Comparative Pharmacology
Head-to-head clinical analysis: AUROVELA 24 FE versus BREVICON 28 DAY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUROVELA 24 FE versus BREVICON 28 DAY.
AUROVELA 24 FE vs BREVICON 28-DAY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination hormonal contraceptive. Norethindrone acetate suppresses gonadotropin release (FSH and LH) via progestogenic activity, inhibiting ovulation. Ethinyl estradiol provides negative feedback on hypothalamic-pituitary axis, further suppressing gonadotropins and stabilizing endometrium.
Combination oral contraceptive; ethinyl estradiol and norethindrone suppress gonadotropin secretion (FSH and LH) via negative feedback, inhibiting ovulation. Additionally, alters cervical mucus consistency and endometrial lining to impede sperm penetration and implantation.
One tablet (0.10 mg ethinyl estradiol / 1.0 mg norethindrone acetate) orally once daily for 24 days, followed by 4 days of ferrous fumarate 75 mg tablets (placebo). Administer at the same time each day without interruption.
One tablet (0.5 mg norethindrone and 35 mcg ethinyl estradiol) orally once daily for 28 days (21 active tablets followed by 7 inert tablets).
None Documented
None Documented
Norethindrone: 7-8 hours; Ethinyl estradiol: 13-16 hours. Steady-state achieved within 5 days.
Norethindrone: 8-11 hours; Ethinyl estradiol: 13-27 hours; half-life for ethinyl estradiol allows once-daily dosing
Norethindrone: ~40% renal, ~60% fecal; Ethinyl estradiol: ~40% renal, ~60% fecal as glucuronide and sulfate conjugates.
Renal: ~40% as metabolites and unchanged drug; fecal/biliary: ~60% as metabolites
Category C
Category C
Oral Contraceptive
Oral Contraceptive